Compare Globus Medical Inc. Class A Common Stock (GMED) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Royal Caribbean Cruises Ltd — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Royal Caribbean Cruises Ltd trades at $275 (market cap $73.36B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 7.2× Globus Medical Inc. Class A Common Stock's market cap, and Royal Caribbean Cruises Ltd pays a 2.19% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Royal Caribbean Cruises Ltd for 85 Days on average.
| GMED | RCL | |
|---|---|---|
Market Cap | $10.25B | $73.36B |
Volume | 1,059,528 | 1,222,673 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $348.03 |
52-Week Low | $58.33 | $230.30 |
Typical Hold Time | 0 Days | 85 Days |
Enterprise Value | $9.76B | $96.01B |
Dividend Yield | — | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Royal Caribbean (RCL) trades at $281.51, up 0.3% with a bullish technical signal. The company shows strong fundamental momentum with Q1 and Q2 2026 earnings beats, robust profitability (23.5% net margin), and improving cash flow. Recent news highlights a $3 billion Sandals Resorts acquisition expanding into the resort market. Technical indicators show the stock trading near pivot point resistance at $285 with strong support at $276.
RCL presents a compelling growth story with accelerating revenue and earnings, though faces execution risks from the Sandals integration and fuel cost pressures. Analyst consensus remains bullish with a $344 price target representing 22% upside potential. The stock's premium valuation (P/E 17.4) appears justified by strong ROE (45.3%) and consistent earnings outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
